Emergency use authorization of Hydroxychloroquine revoked by U.S. FDA
Category: #health  By Pankaj Singh  Date: 2020-06-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Emergency use authorization of Hydroxychloroquine revoked by U.S. FDA

The malaria drug Hydroxychloroquine has been in the headline for the past few months. The drug was hailed as the game-changer in the treatment of COVID-19 by U.S. President Donald Trump. However, the U.S.FDA (Food and Drug Administration) has reportedly revoked its decision that allows emergency use of chloroquine and hydroxychloroquine for treating hospitalized people with COVID-19.

Based on the findings of emerging scientific data and ongoing analysis of EUA( Emergency Use Authorization), the agency concluded that hydroxychloroquine and chloroquine are not effective in the treatment of COVID-19.The clinical trials of malaria drugs also reported several serious adverse events such as high cardiac risk. The potential and known benefits of chloroquine and hydroxychloroquine no longer outweigh the potential and known risk for authorized use.

Previously, the U.S FDA granted the EUA on 28 March based on the findings of available data at the time. Today, BARDA (Biomedical Advanced Research and Development Authority) sent a letter to the agency requesting the cancellation of the EUA based on updated data.

Speaking on which, Anand Shah, M.D, Deputy Commissioner for Medical and Scientific Affairs at U.S FDA said that the agency’s decisions regarding EUA may evolve as per the updated data and considering the balance of risk against benefits for the treatment of COVID-19.

Mr. Shah added that the agency always underpins its decision-making with high quality, most trustworthy, and up-to-date evidence available. It would continue to evaluate all of the emergency use authorizations the U.S FDA has granted and made appropriate changes according to evidence, said Mr. Shah.

Hydroxychloroquine and Chloroquine are both U.S FDA-approved to treat or prevent malaria. Recent outcomes from several clinical trials showed that hydroxychloroquine has no benefits in the treatment of COVID-19 and suggested dosing regimens for hydroxychloroquine and chloroquine are unlikely to inhibit and kill the SARC-COV-2.

Source Credit -https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...